Discontinuing Rivaroxaban Before Endoscopy in Patients with Impaired Renal Function and GI Bleeding History

Risk Stratification and Management

For high-risk endoscopy procedures in patients with normal renal function, the American Society for Gastrointestinal Endoscopy recommends stopping rivaroxaban 3 days before the procedure 1, 2
For low-risk procedures, the European Society of Gastrointestinal Endoscopy suggests omitting only the morning dose on the day of the procedure or discontinuing 1 day (2 doses) before the procedure 1, 2
The American College of Cardiology recommends adjusting the timing of rivaroxaban discontinuation based on creatinine clearance (CrCl) for high-risk procedures: CrCl >80 mL/min, stop 2 days before; CrCl 50-80 mL/min, stop 3 days before; CrCl 30-50 mL/min, stop 4 days before; CrCl 15-30 mL/min, stop at least 4 days before 1, 2, 3
Renal function should be checked immediately before the procedure if the patient is clinically deteriorating, as this affects drug clearance 1, 2

The American Society for Gastrointestinal Endoscopy recommends against using bridging anticoagulation with heparin products, as it increases major hemorrhage rates without reducing thrombosis 1
Rivaroxaban should be resumed based on the bleeding risk of the procedure: low bleeding risk procedures, resume 1 day after; high bleeding risk procedures, resume 2-3 days after 1, 2
The European Society of Cardiology notes that rivaroxaban achieves full anticoagulant activity within 3 hours of the first dose, ensuring adequate hemostasis before resumption 1, 4

The American College of Cardiology recommends consulting hematology if the patient has rapidly deteriorating renal function or uncertainty about the safety of proceeding 1, 2
The European Society of Cardiology suggests consulting cardiology regarding thrombotic risk, particularly if the patient has coronary stents or recent thrombotic events 5
Routine coagulation monitoring is not recommended, but anti-factor Xa assays with rivaroxaban-specific calibrators can quantify drug levels if needed 1

Rivaroxaban is a direct competitive inhibitor of factor Xa with rapid absorption and a half-life of 7-11 hours 6, 7
Two-thirds of rivaroxaban is metabolized in the liver, but it can be used in patients with liver disease as long as there is no coagulopathy 6, 8
Only about one-third of active rivaroxaban is cleared by the kidneys with no accumulation when creatinine clearance (CrCl) is above 15 mL/min 6

Dose reduction to 15 mg once daily is recommended for patients with CrCl between 15-30 mL/min 6, 7
Rivaroxaban is not recommended when CrCl is ≤15 mL/min 6, 7

Lower gastrointestinal bleeding occurs more frequently in elderly patients with rivaroxaban compared to warfarin 6, 9
Age ≥75 years is associated with increased risk of GI bleeding 10

Patients with gastric or gastroesophageal tumors are at increased risk for hemorrhage with direct oral anticoagulants including rivaroxaban; LMWH may be preferred in these patients 11
Rivaroxaban should be used with caution in patients with a history of gastrointestinal disorders due to the increased risk of bleeding 9

The effect of rivaroxaban on coagulation tests can be reversed by prothrombin complex concentrate (50 IU/kg of 4-factor concentrate) 6
Anti-factor Xa assays with specific rivaroxaban calibrators can be used to determine drug concentration if needed 6

Avoid rivaroxaban in patients with active bleeding 10
Avoid combination with antiplatelets, thrombolytics, NSAIDs, SNRIs, or SSRIs when possible 10
Consider proton pump inhibitors in patients at high risk of GI bleeding 10